Abivax SA, a biotech firm focused on inflammatory diseases, will report its Q3 2026 earnings on September 21. Analysts expect a loss with EPS at -$0.98 and revenue around $799,000. The stock recently reacted positively to FDA feedback on its drug Obefazimod, boosting optimism and price targets despite the company’s current unprofitability. Investors will watch closely for insights on future prospects and financial health, which remains strong with a high current ratio and low debt.
Abivax SA earnings preview provides context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Sep 21, 2026 20:01 WIB: 56 of 95 priced US health-sector stocks rose, 25 fell. Notable movers include RXRX at USD 3.90 (+1.83%), TWST at USD 170.00 (+1.80%), and BNGO at USD 1.70 (-1.73%). Typical hold times on Pluang range from 22 to 48 days for these stocks.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Faruqi & Faruqi, LLP is investigating claims against Ardelyx for allegedly misleading investors about the commercial performance of its drugs XPHOZAH and IBSRELA. The lawsuit alleges Ardelyx failed to disclose increasing payer restrictions that hurt ...
